{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.13","upperLimit":"18.55","value":"6.53"},{"groupId":"OG001","lowerLimit":"3.87","upperLimit":"16.84","value":"7.79"},{"groupId":"OG002","lowerLimit":"5.96","upperLimit":"10.46","value":"8.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent oral clearance are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received oral erlotinib during maintenance therapy cycle B2 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1, 2, 4, 8, and 24 hours post-dose","title":"Erlotinib Apparent Oral Clearance","type":"SECONDARY","unitOfMeasure":"L/h/m^2"}